Stocks & Investing
Tue, April 5, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, October 8, 2021
[ 12:00 AM ] - WOPRAI
Fri, August 20, 2021
[ 12:00 AM ] - WOPRAI
Thu, July 15, 2021
[ 12:00 AM ] - WOPRAI
Tue, July 13, 2021
[ 12:00 AM ] - WOPRAI
Thu, May 13, 2021
[ 12:00 AM ] - WOPRAI
Mon, December 14, 2020
[ 12:00 AM ] - WOPRAI
Thu, November 12, 2020
[ 12:00 AM ] - WOPRAI
Tue, November 10, 2020
[ 12:00 AM ] - WOPRAI
Mon, November 9, 2020
[ 12:00 AM ] - WOPRAI
Thu, September 10, 2020
[ 12:00 AM ] - WOPRAI
Tue, July 21, 2020
[ 12:00 AM ] - WOPRAI
Mon, July 13, 2020
[ 12:00 AM ] - WOPRAI
Thu, April 30, 2020
[ 12:00 AM ] - WOPRAI
Fri, April 3, 2020
[ 12:00 AM ] - WOPRAI
Mon, February 24, 2020
[ 12:00 AM ] - WOPRAI
Tue, May 21, 2019
[ 12:00 AM ] - WOPRAI
Wed, August 15, 2018
[ 12:00 AM ] - WOPRAI
Fri, June 29, 2018
[ 12:00 AM ] - WOPRAI
Thu, March 29, 2018
[ 12:00 AM ] - WOPRAI
Wed, September 20, 2017
[ 12:00 AM ] - WOPRAI
Thu, August 3, 2017
[ 12:00 AM ] - WOPRAI
Fri, August 5, 2016 Arlinda Lee Maintained (BNTX) at Strong Buy with Decreased Target to $300 on, Apr 5th, 2022
Arlinda Lee of Canaccord Genuity, Maintained "BioNTech SE" (BNTX) at Strong Buy with Decreased Target from $450 to $300 on, Apr 5th, 2022.
Arlinda has made no other calls on BNTX in the last 4 months.
There are 4 other peers that have a rating on BNTX. Out of the 4 peers that are also analyzing BNTX, 3 agree with Arlinda's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold and Held Target at $200 on, Friday, April 1st, 2022
- Simon Baker of "Redburn Partners" Upgraded from Strong Sell to Hold on, Tuesday, February 1st, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $217 on, Tuesday, February 1st, 2022
This is the rating of the analyst that currently disagrees with Arlinda
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $339 on, Wednesday, February 23rd, 2022
